I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Polycystic ovary syndrome (PCOS) is an anovulatory disease caused by dysfunctional reproductive endocrinology.\[[@ref1]\] Insulin resistance (IR) and compensatory hyperinsulinemia are considered as the important pathogenic factors in PCOS. When the compensatory hyperinsulinemia fails to meet the needs of the body, carbohydrate metabolism disorders may develop.\[[@ref2]\] Hyperinsulinemia can ultimately result in hyperandrogenism. Obesity is also a characteristic feature in women suffering from PCOS, whereby approximately 40--50% of women with PCOS are overweight or obese.\[[@ref3][@ref4][@ref5]\] Obesity, in addition to metabolic syndrome and dyslipidemia, is a risk factor of cardiovascular disease (CVD) in women with PCOS.\[[@ref6]\]

Evidence-based guidelines recommend lifestyle modifications as the first line treatment for PCOS,\[[@ref7]\] however, the engagement, compliance, and sustainability remain challenging. Metformin, a biguanide used to treat noninsulin-dependent diabetes and the most thoroughly investigated insulin-sensitizing agent, has been used to treat patients with PCOS and IR. Metformin reduces IR and inhibits ovarian androgen production in PCOS patients via effects on steroidogenic acute regulatory protein and 17α-hydroxylase.\[[@ref8][@ref9][@ref10]\] It has been suggested that metformin might play a key role in PCOS when combined with lifestyle changes, to assist in weight management and cycle regulation.\[[@ref11]\]

Combined oral contraceptives (COCs) have been used for many years in the treatment of PCOS.\[[@ref12]\] It is known that COCs may have negative effects on carbohydrate metabolism and the lipid profiles;\[[@ref13][@ref14]\] however, it is not well understood. Cyproterone acetate (CPA)-containing COCs are commonly recommended for anti-hyperandrogenism in PCOS, as CPA has high antiandrogenic activity. However, some controversy remains regarding whether CPA has a transiently negative effect on carbohydrate metabolism and lipid profiles.\[[@ref15][@ref16][@ref17]\] A number of studies have also investigated the combination of metformin and COCs in women with PCOS and suggested that it may improve the insulin sensitivity.\[[@ref18][@ref19][@ref20]\] The addition of metformin to COCs may, therefore, have metabolic benefits in the treatment of women with PCOS.

Drospirenone (DRP), another steroidal progestin, has antiandrogenic and antimineralocorticoid activities which other progestins lack.\[[@ref21]\] Combined with 30-μg ethinyl estradiol (EE), it has previously been used as DRP/EE COCs in the treatment of PCOS.\[[@ref22][@ref23][@ref24][@ref25]\] In recent years, studies have showed that the DRP-containing COCs had no negative metabolic effects on women with PCOS, and some studies reported favorable metabolic effects.\[[@ref21][@ref23][@ref24][@ref25][@ref26]\] However, few studies have investigated the combination of DRP-containing COCs and metformin,\[[@ref27][@ref28]\] and the effects of DRP-containing COCs on carbohydrate and lipid metabolism in women with PCOS and dysfunctional metabolism have not, to date, been investigated.

In the current study, we designed a randomized clinical trial to compare the metabolic effect of DRP-containing COCs with the more widely used CPA-containing COCs, combined with metformin and lifestyle modifications, in women with PCOS and dysfunctional metabolism. We also aimed to determine whether DRP-containing COCs have more beneficial effects on carbohydrate metabolism and lipid profiles.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Study population {#sec2-1}
----------------

This randomized controlled trial (Chinese Clinical Trial Registry, ChiCTR-TRC-11001143) was conducted between January 2011 and January 2013, at the West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China. Randomization was performed using a random-number table. The study was not blinded as group allocation was not concealed. The study protocol was approved by the Medical Ethics Committee of the West China Second University Hospital of Sichuan University. Informed written consent was obtained from all participants and/or their parents. A total of 248 women with amenorrhea or oligomenorrhea were screened for PCOS according to the Rotterdam diagnostic criteria,\[[@ref29]\] and 27 patients were excluded as not meeting the PCOS diagnostic criteria. The remaining 221 patients were further examined, and women with a body mass index (BMI) ≥25 kg/m^2^ and/or homeostasis model assessment-insulin resistance (HOMA-IR) of ≥2.77, were included in the study. Patients with contraindications to taking COCs, women aged \>40 years, smokers, and women with a history of alcohol abuse were excluded from the study. A total of 99 women were finally included in the study \[[Figure 1](#F1){ref-type="fig"}\].

![The flowchart of this study. PCOS: Polycystic ovary syndrome; DRP: Drospirenone; CPA: Cyproterone acetate.](CMJ-129-883-g001){#F1}

Drug administration and implementation of lifestyle modifications {#sec2-2}
-----------------------------------------------------------------

Participants were randomized either to the DRP group (receiving 3 mg DRP plus 30 μg EE/tablet) or the CPA group (receiving 2 mg CPA plus 35 μg EE/tablet). Treatment regimens for both groups were similar: COC administration was commenced on the 1^st^ day of the menstrual cycle or withdrawal of bleeding was continued for 21 consecutive days followed by a 7-day interval and repeated for six cycles. All participants simultaneously took metformin (0.5 g/d), and lifestyle modifications (modification of diet and increased physical activities for control of body weight) were implemented during COC treatment. A low-glycaemic index carbohydrate foods regimen and regular aerobic exercise were recommended to all participants. Meantime, all participants were advised to have a regular aerobic exercise (such as walking and jogging) up to 40 min per session, at least 3 times/week. The starting dose of metformin was 0.5 g/d, and patients gradually adjusted the dose to the full dosage of 1.5 g/d. Any medications known to affect carbohydrate metabolism or sex hormones, including COCs, progestins, and estrogen-progestin combinations, were discontinued for at least 3 months before enrollment in the study. Subjects were not permitted to use any lipid- or blood pressure (BP)-lowering drugs.

Hematological parameters {#sec2-3}
------------------------

Blood samples were collected from all subjects during the early follicular phase of their cycles (3--5 days after the onset of spontaneous or progestin-induced menstrual bleeding). Height, weight, and waist and hip circumferences were measured in the morning of fasting-blood collection; BMI and the waist-to-hip ratio (WHR) were calculated. BP was measured in each woman after resting for 30 min. The amount of excess terminal hair growth was assessed using a modified Ferriman-Gallwey (F-G) method.\[[@ref30]\] The global acne grading system (GAGS) was used for the severity of acne.\[[@ref31]\] All the above measurements and scores were made jointly by two observers throughout the trial.

The measurements of serum estradiol (E2), progesterone (P), testosterone (T), luteinizing hormone, follicle-stimulating hormone, prolactin, and insulin were made by chemiluminescent immunoassay analysis (Advia Centaur, Siemens, Erlangen, Germany). The intra- and inter-assay variability was \<6.25%. Plasma glucose was measured by the hexokinase method (ADVI 2400, Siemens, Erlangen, Germany). The intra- and inter-assay variability was \<2.5%. An oral glucose tolerance test (OGTT) was also performed. Blood samples were collected before administration of a 75-g oral glucose load and after 30, 60, 120, and 180 min. From the OGTT, area under the curve (AUC) data for insulin and glucose were obtained. The AUCs were calculated using the trapezoidal rule and expressed as μU/ml × 3 h. HOMA-IR was calculated using the following formula: (blood glucose \[mmol/L\] × insulin \[μU/ml\])/22.5. The total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride (TG) concentrations were measured by an enzymatic method (ADVI 2400, Siemens, Germany), for which the intra- and inter-assay variability was \<7.5%. The predicted risks for CVD (TC/HDL and LDL/HDL ratios) were calculated from these analyses.

On the third cycle, the participants reported their compliance to drug administration and lifestyle modifications through the telephone or coming back to the hospital. After the sixth cycle, the participants came back to the hospital and all the clinical characteristics and biochemical profiles were tested again. The blood samples for biological parameters were obtained between day 3 and day 5 of the sixth COC withdrawal bleeding.

Statistical analysis {#sec2-4}
--------------------

Continuous variables were expressed as mean ± standard deviation (SD) or as the median (P~25~, P~75~) if the variable was not normally distributed, using the Shapiro--Wilk test. Comparisons for continuous variables were evaluated with the Student\'s *t*-test, or the Wilcoxon signed rank test when the data were not normally distributed. Analysis of covariance was used to control for age, BMI, and baseline data of each analyzed parameter when compared between the two groups. *P* values and confidence intervals were estimated in a two-tailed fashion. A value of *P* \< 0.05 was considered statistically significant. All data were analyzed using Statistical Analysis System version 8.0 software (SAS Institute, Cary, NC, USA).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 99 patients aged 16--33 years were included in the study. Of these women, only 68 participants (DRP: *n* = 32; CPA: *n* = 36) completed the 6-month treatment, others withdrew from the study due to side effects, moving away or unwillingness to adhere to therapy guidelines.

All participants had regular withdrawal bleeding during COC treatment. Some participants (four women from the DRP group and five women from the CPA group) experienced spotting during the 1^st^ month of COC use, which subsequently stopped during the second cycle. On the 3^rd^ month\'s visit, there were 63 patients taking the full dosage (1.5 g/d) of metformin and the left 5 took 1.0 g/d of metformin because of gastrointestinal events. Since the 4^th^ month of treatment, all participants had taken the full dosage of metformin and lasted to the end of the study.

Effects of treatments on clinical and metabolic characteristics before and after treatment {#sec2-5}
------------------------------------------------------------------------------------------

There was no statistically significant difference between baseline clinical, endocrine, and metabolic parameters of the enrolled participants between the DRP and CPA groups \[Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}\]. The clinical and metabolic parameters before and after treatment in both groups are shown in [Table 3](#T3){ref-type="table"}. The combination regimen of COC, metformin, and lifestyle modifications in these patients resulted in a significant decrease of BMI when compared to baseline levels in both the DRP and CPA groups (21.76 \[20.54, 25.21\] kg/m^2^ vs. 21.42 \[19.65, 22.51\] kg/m^2^, *P* \< 0.001;24.01 \[21.45, 25.62\] kg/m^2^ vs. 21.62 \[20.72, 24.65\] kg/m^2^, *P* \< 0.001, respectively), although the difference in waist circumference and WHR did not reach statistical significance. The GAGS and F-G scores were significantly decreased after treatment in both DRP and CPA groups (2 \[0, 4\] vs. 0 \[0, 0\], *P* \< 0.001 and 2.0 \[0.5, 5.0\] vs. 1.0 \[0, 4.0\], *P* = 0.013;3 \[0, 8\] vs. 0 \[0, 0\], *P* \< 0.001 and 3.0 \[1.0, 4.0\] vs. 2.0 \[0, 3.0\], *P* = 0.001, respectively). A statistically insignificant trend was observed in falling systolic BP with treatment in the DRP group whereas an upward diastolic BP trend (75.14 ± 6.77 mmHg vs. 80.70 ± 5.60 mmHg, *P* \< 0.001) was observed in the CPA group.

###### 

Basal clinical characteristics of patients with polycystic ovary syndrome and metabolic disorders enrolled in the two groups

  Items             DRP group (*n* = 50)   CPA group (*n* = 49)   Statistics   *P*
  ----------------- ---------------------- ---------------------- ------------ -------
  Age (years)       23.5 ± 4.9             24.3 ± 4.0             0.863\*      0.391
  BMI (kg/m^2^)     23.00 (20.77, 26.76)   24.07 (21.54, 26.71)   −0.846^†^    0.398
  Hirsutism (F-G)   2.0 (0, 5.0)           3.0 (1.0, 4.0)         −0.586^†^    0.558
  Acne (GAGS)       2 (0, 5)               2 (0, 8)               −1.085^†^    0.278
  WC (cm)           82.0 (78.0, 92.0)      87.5 (79.0, 94.0)      −1.440^†^    0.150
  WHR               0.89 ± 0.05            0.91 ± 0.06            1.298\*      0.197
  SBP (mmHg)        117.96 ± 13.29         118.06 ± 11.45         0.041\*      0.967
  DBP (mmHg)        75.54 ± 8.06           76.12 ± 7.73           0.362\*      0.718

Values were showed as mean ± SD or as the median (P~25~, P~75~). \*: *t* values; ^†^: *Z* values; BMI: Body mass index; WC: Waist circumference; WHR: Waist-to-hip ratio; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; DRP: Drospirenone; CPA: Cyproterone acetate; F-G: Ferriman--Gallwey; GAGS: Global acne grading system; SD: Standard deviation.

###### 

Basal hormonal and metabolic levels of patients with polycystic ovary syndrome and metabolic disorders enrolled in the two groups

  Items                               DRP group (*n* = 50)         CPA group (*n* = 49)          Statistics   *P*
  ----------------------------------- ---------------------------- ----------------------------- ------------ -------
  E2 (pg/ml)                          58.68 ± 14.83                58.97 ± 17.39                 1.091\*      0.087
  P (ng/ml)                           0.47 (0.34, 0.66)            0.48 (0.28, 0.72)             −0.078^†^    0.938
  T (ng/ml)                           0.63 ± 0.18                  0.63 ± 0.22                   0.037\*      0.971
  LH (mU/ml)                          11.01 ± 6.01                 10.10 ± 7.06                  −0.641\*     0.523
  FSH (mU/ml)                         5.59 ± 1.67                  5.36 ± 2.26                   −0.575\*     0.567
  PRL (ng/ml)                         13.97 ± 8.06                 15.51 ± 9.06                  0.883\*      0.379
  LH/FSH                              1.76 (1.08, 2.59)            1.85 (1.20, 2.22)             −0.072^†^    0.943
  FPG (mmol/L)                        5.44 ± 0.45                  5.63 ± 0.77                   1.481\*      0.142
  FINS (µU/ml)                        14.90 (12.40, 18.00)         14.95 (10.38, 20.93)          −0.495^†^    0.621
  HOMA-IR                             3.73 (2.89, 4.34)            3.83 (2.90, 5.45)             −0.794^†^    0.427
  AUC~glucose~ (mmol∙L^−1^∙min^−1^)   421.40 (360.80, 492.60)      480.60 (372.60, 539.20)       −1.446^†^    0.148
  AUC~insulin~ (µU∙ml^−1^∙ min^−1^)   6361.60 (4114.60, 7752.60)   6694.60 (4100.60, 10931.20)   −1.019^†^    0.308
  HbA1c (%)                           5.41 ± 0.30                  5.51 ± 0.44                   1.261\*      0.210
  TC (mmol/L)                         4.23 ± 0.81                  4.41 ± 0.77                   1.113\*      0.269
  TG (mmol/L)                         1.05 (0.82, 1.38)            1.42 (0.77, 1.79)             −1.526^†^    0.127
  HDL-C (mmol/L)                      1.23 (1.08, 1.44)            1.22 (1.08, 1.40)             −0.152^†^    0.880
  LDL-C (mmol/L)                      2.51 ± 0.75                  2.57 ± 0.63                   0.432\*      0.668
  LDL/HDL                             2.05 ± 0.73                  2.14 ± 0.75                   0.607\*      0.545
  TC/HDL                              3.42 ± 0.83                  3.62 ± 1.02                   1.101\*      0.274

Values were showed as mean ± SD or as the median (P~25~, P~75~). \*: *t* values; ^†^: *Z* values; E2: Estradiol; P: Progesterone; T: Testosterone; LH: Luteinizing hormone; FSH: Follicle-stimulating hormone; PRL: Prolactin; FPG: Fasting plasma glucose; FINS: Fasting insulin; HOMA-IR: Homeostasis model assessment-insulin resistance; AUC~glucose~: Area under the curve of glucose; AUC~insulin~: Area under the curve of insulin; HbA1c: Glycated hemoglobin; TC: Total cholesterol; TG: Triglycerides; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; DRP: Drospirenone; CPA: Cyproterone acetate; SD: Standard deviation.

###### 

Clinical and metabolic characteristics before and after treatment in DRP (*n* = 32) and CPA groups (*n* = 36)

  Items                                Group   Before treatment               After treatment              Statistics   *P*
  ------------------------------------ ------- ------------------------------ ---------------------------- ------------ ---------
  BMI (kg/m^2^)                        DRP     21.76 (20.54, 25.21)           21.42 (19.65, 22.51)         −4.124\*     \<0.001
                                       CPA     24.01 (21.45, 25.62)           21.62 (20.72, 24.65)         −3.857\*     \<0.001
  Hirsutism (F-G)                      DRP     2.0 (0.5, 5.0)                 1.0 (0, 4.0)                 −2.489\*     0.013
                                       CPA     3.0 (1.0, 4.0)                 2.0 (0, 3.0)                 −3.217\*     0.001
  Acne (GAGS)                          DRP     2 (0, 4)                       0 (0, 0)                     −3.753\*     \<0.001
                                       CPA     3 (0, 8)                       0 (0, 0)                     −4.384\*     \<0.001
  WHR                                  DRP     0.89 ± 0.05                    0.92 ± 0.12                  −1.455^†^    0.156
                                       CPA     0.91 ± 0.07                    0.91 ± 0.05                  0.253^†^     0.802
  SBP (mmHg)                           DRP     116.10 ± 13.38                 112.80 ± 10.62               1.137^†^     0.265
                                       CPA     118.39 ± 11.06                 120.30 ± 8.53                −0.830^†^    0.412
  DBP (mmHg)                           DRP     75.09 ± 7.87                   77.90 ± 9.50                 −1.634^†^    0.113
                                       CPA     75.14 ± 6.77                   80.70 ± 5.60                 −4.842^†^    \<0.001
  FPG (mmol/L)                         DRP     5.40 ± 0.41                    5.21 ± 0.32                  2.141^†^     0.041
                                       CPA     5.52 ± 0.73                    5.37 ± 0.41                  1.386^†^     0.175
  FINS (µU/ml)                         DRP     13.90 (10.50, 18.40)           10.75 (8.60, 13.50)          −2.335\*     0.020
                                       CPA     13.70 (10.30, 22.80)           17.85 (10.30, 24.40)         −1.462\*     0.144
  HOMA-IR                              DRP     3.74 (2.85, 4.23)              2.55 (1.92, 3.40)            −2.664\*     0.008
                                       CPA     3.85 (2.87, 5.10)              3.90 (2.54, 5.89)            −1.736\*     0.083
  AUC~glucose~ (mmol∙L^−1^∙ min^−1^)   DRP     419.80 (385.80, 486.00)        467.00 (425.40, 513.40)      −2.822\*     0.005
                                       CPA     460.60 (394.60, 526.20)        450.80 (425.00, 524.00)      −0.917\*     0.359
  AUC~insulin~ (µU∙ml^−1^∙ min^−1^)    DRP     6393.80 (4247.80, 7833.60)     5094.60 (4292.20, 7240.60)   −1.960\*     0.051
                                       CPA     6894.60 (4304.60, 10,721.00)   5264.00 (3060.60, 9504.00)   −2.457\*     0.014
  HbA1c (%)                            DRP     5.37 ± 0.28                    5.41 ± 0.28                  −0.606^†^    0.549
                                       CPA     5.51 ± 0.52                    5.51 ± 0.40                  0.094^†^     0.926
  TC (mmol/L)                          DRP     4.18 ± 0.82                    4.84 ± 0.89                  −5.995^†^    \<0.001
                                       CPA     4.40 ± 0.80                    5.20 ± 1.37                  −3.737^†^    \<0.001
  TG (mmol/L)                          DRP     0.95 (0.78, 1.37)              1.30 (0.87, 1.68)            −2.839\*     0.005
                                       CPA     1.30 (0.64, 1.73)              1.32 (0.88, 2.12)            −2.121\*     0.034
  HDL-C (mmol/L)                       DRP     1.24 (1.12, 1.48)              1.67 (1.45, 1.98)            −4.639\*     \<0.001
                                       CPA     1.22 (1.06, 1.48)              1.59 (1.36, 1.89)            −4.865\*     \<0.001
  LDL-C (mmol/L)                       DRP     2.43 ± 0.79                    2.66 ± 0.74                  −2.363^†^    0.025
                                       CPA     2.57 ± 0.66                    2.72 ± 0.83                  −1.407^†^    0.168
  LDL-C/HDL-C                          DRP     1.90 ± 0.72                    1.64 ± 0.50                  2.877^†^     0.007
                                       CPA     2.13 ± 0.87                    1.75 ± 0.70                  4.026^†^     \<0.001
  TC/HDL-C                             DRP     3.24 ± 0.76                    2.95 ± 0.54                  2.711^†^     0.011
                                       CPA     3.61 ± 1.14                    3.41 ± 1.69                  0.603^†^     0.551

Values were showed as mean ± SD or as the median (P~25~, P~75~). \*: *Z* values; ^†^: *t* values. DRP: Drospirenone; CPA: Cyproterone acetate; BMI: Body mass index; WHR: Waist-to-hip ratio; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; FPG: Fasting plasma glucose; FINS: Fasting insulin; HOMA-IR: Homeostasis model assessment-insulin resistance; AUC~glucose~: Area under the curve of glucose; AUC~insulin~: Area under the curve of insulin; HbA1c: Glycated hemoglobin; TC: Total cholesterol; TG: Triglycerides; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; F-G: Ferriman--Gallwey; GAGS: Global acne grading system; SD: Standard deviation.

Fasting glucose, AUC of glucose, and fasting insulin levels changed in both groups, but only reached statistical significance in the DRP group (5.40 ± 0.41 mmol/L vs. 5.21 ± 0.32 mmol/L, *P* = 0.041; 419.80 \[385.80, 486.00\] mmol·L^−1^·min^−1^ vs. 467.00 \[425.40, 513.40\] mmol·L^−1^·min^−1^, *P* = 0.005; 13.90 \[10.50, 18.40\] µU/ml vs. 10.75 \[8.60, 13.50\] µU/ml, *P* = 0.020, respectively). AUC of insulin significantly decreased after treatment in the CPA group (6894.60 \[4304.60, 10,721.00\] µU·ml^−1^·min^−1^ vs. 5264.00 \[3060.60, 9504.00\] µU·ml^−1^·min^−1^, *P* = 0.014) but did not reach statistical significance in the DRP group. HOMA-IR significantly decreased in the DRP group (3.74 \[2.85, 4.23\] vs. 2.55 \[1.92, 3.40\], *P* = 0.008), but not in the CPA group.

In the DRP group, lipid profiles, TC, TG, HDL, and LDL were significantly increased after treatment (4.18 ± 0.82 mmol/L vs. 4.84 ± 0.89 mmol/L, *P* \< 0.001; 0.95 \[0.78, 1.37\] mmol/L vs. 1.30 \[0.87, 1.68\] mmol/L, *P* = 0.005; 1.24 \[1.12, 1.48\] mmol/L vs. 1.67 \[1.45, 1.98\] mmol/L, *P* \< 0.001; 2.43 ± 0.79 mmol/L vs. 2.66 ± 0.74 mmol/L, *P* = 0.025, respectively) while LDL/HDL and TC/HDL ratios decreased significantly (1.90 ± 0.72 vs. 1.64 ± 0.50, *P* = 0.007; 3.24 ± 0.76 vs. 2.95 ± 0.54, *P* = 0.011, respectively). In the CPA group, there was an increase in TC, TG, and HDL (4.40 ± 0.80 mmol/L vs. 5.20 ± 1.37 mmol/L, *P* \< 0.001; 1.30 \[0.64, 1.73\] mmol/L vs. 1.32 \[0.88, 2.12\] mmol/L, *P* \< 0.034; 1.22 \[1.06, 1.48\] mmol/L vs. 1.59 \[1.36, 1.89\] mmol/L, *P* \< 0.001, respectively) and a decrease of LDL/HDL ratio (2.13 ± 0.87 mmol/L vs. 1.75 ± 0.70 mmol/L, *P* \< 0.001).

Effects of treatments on clinical and metabolic profiles between the two groups {#sec2-6}
-------------------------------------------------------------------------------

The relative changes in all studied parameters after 6 months of treatment, compared with the baseline levels in both study groups, are shown in [Table 4](#T4){ref-type="table"}. A statistically significant difference was observed in the systolic BP (4.00 \[--6.00, 13.00\] mmHg vs. --3.50 \[--13.00, 9.00\] mmHg, *P* = 0.009) after treatment between the two groups, but in none of the remaining clinical and metabolic parameters in either study group.

###### 

Clinical and metabolic changes from baseline after 6 months of treatment in DRP and CPA groups

  Items                                DRP group (*n* = 32)       CPA group (*n* = 36)         *F*     *P*
  ------------------------------------ -------------------------- ---------------------------- ------- -------
  BMI (kg/m^2^)                        1.06 (0.42, 2.55)          1.56 (0.12, 2.59)            0.179   0.674
  Hirsutism (F-G)                      0 (0, 1)                   0 (0, 1)                     1.496   0.226
  Acne (GAGS)                          2 (0, 4)                   3 (0, 8)                     1.268   0.265
  WHR                                  −0.01 (−0.03, 0.03)        0 (−0.02, 0.03)              1.081   0.303
  SBP (mmHg)                           4.00 (−6.00, 13.00)        −3.50 (−13.00, 9.00)         7.348   0.009
  DBP (mmHg)                           −4.00 (−9.00, 1.00)        −4.50 (−9.75, −0.25)         1.706   0.196
  FPG (mmol/L)                         0.07 (−0.07, 0.31)         0.01 (−0.11, 0.33)           0.933   0.338
  FINS (μU/ml)                         2.20 (−0.20, 5.90)         2.00 (−1.20, 7.60)           0.001   0.977
  HOMA-IR                              0.56 (0.04, 1.56)          0.56 (−0.43, 1.64)           0.000   0.983
  AUC~glucose~ (mmol∙L^−1^∙ min^−1^)   −49.66 (−85.90, 3.26)      −11.44 (−84.54, 48.34)       0.016   0.899
  AUC~insulin~ (μU∙ml^−1^∙ min^−1^)    938.00 (−858.00, 191.00)   1063.50 (−639.50, 2255.00)   0.006   0.938
  HbA1c (%)                            0 (−0.23, 0.10)            0 (−0.20, 0.20)              0.398   0.531
  TC (mmol/L)                          −0.57 (−1.14, −0.31)       −0.62 (−0.91, −0.32)         1.077   0.304
  TG (mmol/L)                          −0.34 (−0.62, 0.00)        −0.18 (−0.58, 0.22)          0.054   0.817
  HDL-C (mmol/L)                       −0.33 (−0.55, −0.09)       −0.34 (−0.55, −0.1)          0.999   0.322
  LDL-C (mmol/L)                       −0.15 (−0.51, 0.11)        −0.24 (−0.44, 0.29)          0.017   0.897
  LDL-C/HDL-C                          0.27 (−0.06, 0.54)         0.34 (0.09, 0.76)            0.084   0.773
  TC/HDL-C                             0.23 (−0.13, 0.65)         0.18 (−0.09, 1.03)           1.169   0.283

Values were showed as mean ± SD, or as the median (P~25~, P~75~). DRP: Drospirenone; CPA: Cyproterone acetate; BMI: Body mass index; F-G: Ferriman-Gallwey; GAGS: Global acne grading system; WHR: Waist-to-hip ratio; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; FPG: Fasting plasma glucose; FINS: Fasting insulin; HOMA-IR: Homeostasis model assessment-insulin resistance; AUC~glucose~: Area under the curve of glucose; AUC~insulin~: Area under the curve of insulin; HbA1c: Glycated hemoglobin; TC: Total cholesterol; TG: Triglycerides; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; SD: Standard deviation.

Side effects {#sec2-7}
------------

The main adverse events resulting from metformin included gastrointestinal reactions such as nausea, vomiting, diarrhea, or poor appetite, and 6/99 (6.1%) of patients canceled their treatment due to these adverse events during the first 3 months of treatment. As such, a step by step incremental regimen is recommended for the introduction of metformin therapy in future studies.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Here, we investigated the combined effects of metformin and lifestyle modifications in addition to DRP- or CPA-containing COCs on clinical and metabolic parameters in women with PCOS and metabolic disorders. As predicted, there was significant decrease in BMI in both study groups following treatment, and studies have associated reduced BMI with improved carbohydrate metabolism and decreased related CVD risk, in obese women with PCOS. In the current study, both types of COCs were able to relieve hyperandrogenic symptoms such as hirsutism and acne, in line with previous reports.\[[@ref32][@ref33][@ref34][@ref35][@ref36][@ref37]\] Furthermore, the decline in F-G score observed in the present study, which has not been previously reported,\[[@ref38][@ref39]\] may be due to the possibility that metformin and lifestyle modifications combined with COCs can further promote the antiandrogenic effects of COCs. As previously demonstrated, BP (the most important predictor of CVD) showed a declining trend in DRP group, as DRP has antimineralocorticoid activities.\[[@ref21][@ref26]\]

To date, a limited number of short-term studies have assessed the effects of different COCs on carbohydrate metabolism in women with PCOS, and there is still debate on the metabolic effects of COCs. Some studies have suggested that COCs may aggravate IR.\[[@ref34][@ref35]\] However, a study by Cagnacci *et al*.\[[@ref16]\] reported ameliorated insulin sensitivity with CPA-containing COC treatment. Moreover, while some studies have reported no correlation between COCs and carbohydrate metabolism,\[[@ref36][@ref37]\] others have demonstrated favorable effects on carbohydrate metabolism when combined COCs with metformin.\[[@ref18][@ref19][@ref20]\] In the current study, fasting glucose, insulin, and HOMA-IR were significantly improved in the DRP/EE regimen and had no negative effects on the carbohydrate metabolism in women with PCOS and metabolic disorders. Furthermore, the lipid profiles increased significantly in both groups in the present study, increased levels of TC, TG, and LDL cholesterol may increase the risk of CVD. This finding of our study is similar to several previous reports.\[[@ref6][@ref32][@ref33]\] The deterioration in lipid profiles typically relates to the dose of EE and the androgenicity of the progestin used. However, in women with normal baseline lipid levels, the profiles remained within the normal range in the present study although the cardiovascular impact of this remains unknown.\[[@ref40]\] In addition, the level of HDL cholesterol in our study was also significantly increased and may, to some extent, counterbalance the negative effects of the other lipid profiles. Furthermore, decreased levels of atherosclerosis markers and TC/HDL and LDL/HDL ratios were also observed in the current study, which can further reduce CVD risk in women with PCOS and metabolic disorders.

In the current study, while there were more superficial benefits of DRP-containing COCs compared with CPA-containing COCs, when each regimen was combined with metformin and lifestyle modifications, the effects on metabolic parameters were almost identical, with only the change in systolic BP identified as statistically significant between the two regimens. Further studies involving larger sample sizes and longer follow-up periods are necessary to fully elucidate the effects of these treatment regiments on carbohydrate and lipid profiles in women with PCOS and metabolic disorders.

In conclusion, the current study demonstrated that a combination regimen with DRP-containing COCs was beneficial for improving glucose metabolic profiles which, in turn, resulted in reduced BMI and may, therefore lessen CVD risk in women with PCOS and metabolic disorders.
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